Human Health, Society and the Future of Biotech

In 2024, the global biotech market was worth $1.68 trillion. By application, the health segment was responsible for just over half of that figure. Not surprising when you think that healthcare focused biotech companies are battling to solve some of our biggest health concerns; turning an ageing society into a longevity society by supporting longer and healthier lives. In this episode of The Next Five Paul Little, CEO of Vesper Bio discusses frontotemporal dementia and the impact of it on human health and society, the biotech solutions being sort to combat the disease as well as what he describes as a Malthusian crisis around biotech funding. Dr Ann Beliën, Founder and CEO of Rejuvinate Biomed addresses the problems of Sarcopenia, the biotech solutions for the disease and how biotech companies use creative ways to secure funding. Gianmario Verona, President of Human Technopole, highlights the importance of industry collaboration and how innovation centres can help propel the biotech sector forward. 
Sources: FT Resources, WHO, JP Morgan, Alzheimersresearchuk, IQVIA 

This content is paid for by Yes Milano and is produced in partnership with the Financial Times' Commercial Department.

• Health
• Tech